- Bayer AG press release ( OTCPK:BAYZF ): Q2 Non-GAAP EPS of €1.93.
- Revenue of €12.82B (+18.2% Y/Y).
- EBITDA before special items rises to €3.3B (+ 30.0%).
- Free cash flow of €1.1B.
- For fiscal 2022, we now expect to generate currency-adjusted sales of €47 billion to €48 billion (previously: approximately €46 billion). We are now targeting an EBITDA margin before special items of around 26% to 27% (previously: around 26%) on a currency-adjusted basis. Based on the aforementioned sales figure, this would now correspond to EBITDA before special items of around €12.5 billion (previously: around €12.0 billion) on a currency-adjusted basis. We now expect core earnings per share to come in at approximately €7.30 (previously: approximately €7.00) on a currency-adjusted basis.
- Based on the closing exchange rates as of June 30, 2022, we now expect to generate sales of €50 billion to €51 billion (previously: approximately €47 billion). This now corresponds to an increase of about 8% on a currency- and portfolio-adjusted basis (previously: about 5%). We are now targeting an EBITDA margin before special items of approximately 26% to 27% (previously: approximately 26%). Based on the aforementioned sales figure, this would now correspond to EBITDA before special items of around €13.0 billion (previously: around €12.0 billion). We now expect core earnings per share to come in at approximately €7.70 (previously: approximately €7.10).
For further details see:
Bayer AG Non-GAAP EPS of €1.93, revenue of €12.82B; Full-year group outlook raised